The global multiomics market size was estimated to be USD 2.34 billion in 2023 and is expected to reach at USD 11.40 billion by 2034 with a CAGR of 15.48% during the forecast period 2024-2034. Surge in demand for single-cell multiomics, rising advancements in omics technologies, increasing research & development activities, growing focus on development of advanced platforms & multiomics databases, surge in demand for single-cell multiomics, rising prevalence of chronic diseases, increasing collaborations within market players, growing technological developments, and rising introduction of novel single-cell platforms are some of the key factors boosting the market growth.
Rising introduction of novel single-cell platforms is predicted to boost the market growth during the forecast period. Single-cell multiomics technologies generally enable the measurement of various types of molecules from a single individual cell, providing more comprehensive biological insights compared to analyzing each molecular layer from separate cells. As a result of the increasing research and development activities, the demand for advanced systems is on the rise. For instance, in February 2023, BD (Becton, Dickinson, and Company) has introduced the BD Rhapsody HT Xpress System, a single-cell multiomics platform developed to support scientific discoveries in various fields, such as genetic disease research, immunology, cancer, and research on chronic disorders.
By product & service, product was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the ongoing developments, rising new product launches, surge in partnerships within market players to develop novel platforms. For instance, in April 2023, Bio-Techne and Lunaphore have revealed a strategic partnership to collaborate on the development of a completely automated spatial multiomics workflow. This workflow will enable the simultaneous detection of protein and RNA biomarkers on the same slide with hyperplex capabilities. Additionally, service is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for advanced solutions, industry participants are providing a wide range of services with a focus on multiomics, and increasing launch of advanced services.
By type, bulk multiomics was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the various advantages associated with bulk multiomics such as simple experimental process and affordable large-scale sample dissection. Bulk multiomics is crucial for providing a systematic explanation of disease pathogenesis and diverse phenotypes at the individual level. Additionally, single-cell multiomics is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for single-cell multiomics to gain insights into complex biological systems and rising focus on developing & offering products in this category by industry participants, and surge in introduction of advanced solutions. For instance, in August 2023, BioSkryb Genomics, known for its groundbreaking single-cell multiomic research solutions, has enhanced the high-throughput capabilities of its ResolveDNA Single-Cell Whole Genome Amplification technology. They have achieved this by optimizing it for use with HP's new D100 Single Cell Dispenser, enabling the large-scale delivery of single-cell genomics.
By platform, genomics was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the increasing emphasis on the development of advanced products within the genomics industry and growing launch of new genomic data interpretation products. For instance, in May 2023, Google Cloud has launched an AI-powered Multiomics Suite, which can assist in the interpretation of genomic data and the design of precision treatments. Additionally, metabolomics is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of cancer and growing number of studies that concentrate on employing multiomics approaches for cancer research.
By application, cell biology was the highest revenue-grossing segment in the global multiomics market in 2023. The integration of multiomics approaches is bringing about a revolution in our comprehension of cellular biology, encompassing both healthy and diseased states. Furthermore, there are numerous solutions available to better understand cell biology. Additionally, oncology is predicted to grow at fastest CAGR during the forecast period owing to the increasing burden of cancer and increasing application of multiomics in cancer research & diagnostics. Researchers and companies are actively engaged in multiple initiatives aimed at assisting cancer patients through the use of multi-omic methodologies. For instance, in September 2022, Freenome, a biotechnology company, initiated the Sanderson Study, which combines its multiomics platform with real-world data to detect multiple types of cancer.
By end-user, academic & research institutes was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the growing studies & research that center on multiomics approaches, encompassing genomics, proteomics, metabolomics, & transcriptomics and increasing funding & investment for research activites. For instance, in September 2023, The National Institutes of Health (NIH) is creating the Multi-Omics for Health and Disease Consortium, and in its first year, it has allocated around $11 million in funding for the consortium. The primary goal of this new consortium is to advance the generation and analysis of "multi-omic" data for human health research. Additionally, pharmaceutical & biotechnology companies is predicted to grow at fastest CAGR during the forecast period owing to the significant benefits of multiomics technologies in drug discovery, development, & personalized medicine and rising adoption of multiomics by biotechnology & pharmaceutical firms to accelerate drug discovery & development.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of leading market players, growing collaborations within market players, and rising introduction of advanced solutions. For instance, in April 2023, Biomodal, previously known as Cambridge Epigenetix, has launched a novel Duet Multiomics Solution. This solution allows for the simultaneous phased reading of both epigenetic and genetic information in a single, low-volume sample. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic conditions, surge in adoption of innovative products for analysis & visualization, growing technological advancements, and rising initiatives by market players. For instance, in September 2023, MGI, a company specializing in life science technology and tools, has unveiled the DCS Lab Initiative aimed at promoting vital scientific research and facilitating the establishment of large-scale multiomics laboratories. Within this initiative, MGI is offering products for various applications such as cell omics, DNA sequencing, and spatial omics, all based on DNBSEQ technologies, to designated research institutions worldwide.
Rising introduction of novel single-cell platforms is predicted to boost the market growth during the forecast period. Single-cell multiomics technologies generally enable the measurement of various types of molecules from a single individual cell, providing more comprehensive biological insights compared to analyzing each molecular layer from separate cells. As a result of the increasing research and development activities, the demand for advanced systems is on the rise. For instance, in February 2023, BD (Becton, Dickinson, and Company) has introduced the BD Rhapsody HT Xpress System, a single-cell multiomics platform developed to support scientific discoveries in various fields, such as genetic disease research, immunology, cancer, and research on chronic disorders.
By product & service, product was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the ongoing developments, rising new product launches, surge in partnerships within market players to develop novel platforms. For instance, in April 2023, Bio-Techne and Lunaphore have revealed a strategic partnership to collaborate on the development of a completely automated spatial multiomics workflow. This workflow will enable the simultaneous detection of protein and RNA biomarkers on the same slide with hyperplex capabilities. Additionally, service is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for advanced solutions, industry participants are providing a wide range of services with a focus on multiomics, and increasing launch of advanced services.
By type, bulk multiomics was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the various advantages associated with bulk multiomics such as simple experimental process and affordable large-scale sample dissection. Bulk multiomics is crucial for providing a systematic explanation of disease pathogenesis and diverse phenotypes at the individual level. Additionally, single-cell multiomics is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for single-cell multiomics to gain insights into complex biological systems and rising focus on developing & offering products in this category by industry participants, and surge in introduction of advanced solutions. For instance, in August 2023, BioSkryb Genomics, known for its groundbreaking single-cell multiomic research solutions, has enhanced the high-throughput capabilities of its ResolveDNA Single-Cell Whole Genome Amplification technology. They have achieved this by optimizing it for use with HP's new D100 Single Cell Dispenser, enabling the large-scale delivery of single-cell genomics.
By platform, genomics was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the increasing emphasis on the development of advanced products within the genomics industry and growing launch of new genomic data interpretation products. For instance, in May 2023, Google Cloud has launched an AI-powered Multiomics Suite, which can assist in the interpretation of genomic data and the design of precision treatments. Additionally, metabolomics is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of cancer and growing number of studies that concentrate on employing multiomics approaches for cancer research.
By application, cell biology was the highest revenue-grossing segment in the global multiomics market in 2023. The integration of multiomics approaches is bringing about a revolution in our comprehension of cellular biology, encompassing both healthy and diseased states. Furthermore, there are numerous solutions available to better understand cell biology. Additionally, oncology is predicted to grow at fastest CAGR during the forecast period owing to the increasing burden of cancer and increasing application of multiomics in cancer research & diagnostics. Researchers and companies are actively engaged in multiple initiatives aimed at assisting cancer patients through the use of multi-omic methodologies. For instance, in September 2022, Freenome, a biotechnology company, initiated the Sanderson Study, which combines its multiomics platform with real-world data to detect multiple types of cancer.
By end-user, academic & research institutes was the highest revenue-grossing segment in the global multiomics market in 2023 owing to the growing studies & research that center on multiomics approaches, encompassing genomics, proteomics, metabolomics, & transcriptomics and increasing funding & investment for research activites. For instance, in September 2023, The National Institutes of Health (NIH) is creating the Multi-Omics for Health and Disease Consortium, and in its first year, it has allocated around $11 million in funding for the consortium. The primary goal of this new consortium is to advance the generation and analysis of "multi-omic" data for human health research. Additionally, pharmaceutical & biotechnology companies is predicted to grow at fastest CAGR during the forecast period owing to the significant benefits of multiomics technologies in drug discovery, development, & personalized medicine and rising adoption of multiomics by biotechnology & pharmaceutical firms to accelerate drug discovery & development.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of leading market players, growing collaborations within market players, and rising introduction of advanced solutions. For instance, in April 2023, Biomodal, previously known as Cambridge Epigenetix, has launched a novel Duet Multiomics Solution. This solution allows for the simultaneous phased reading of both epigenetic and genetic information in a single, low-volume sample. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic conditions, surge in adoption of innovative products for analysis & visualization, growing technological advancements, and rising initiatives by market players. For instance, in September 2023, MGI, a company specializing in life science technology and tools, has unveiled the DCS Lab Initiative aimed at promoting vital scientific research and facilitating the establishment of large-scale multiomics laboratories. Within this initiative, MGI is offering products for various applications such as cell omics, DNA sequencing, and spatial omics, all based on DNBSEQ technologies, to designated research institutions worldwide.
Segmentation: Multiomics Market Report 2023 - 2034
Multiomics Market Analysis & Forecast by Product & Service 2023 - 2034 (Revenue USD Bn)
- Services
- Products
- Consumables
- Software
- Instruments
Multiomics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Bulk Multiomics
- Single-cell Multiomics
Multiomics Market Analysis & Forecast by Platform 2023 - 2034 (Revenue USD Bn)
- Transcriptomics
- Genomics
- Metabolomics
- Proteomics
- Integrated Omics Platforms
Multiomics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Neurology
- Oncology
- Cell Biology
- Immunology
Multiomics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
Multiomics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Multiomics Market: Products & Services Estimates & Trend Analysis
8. Multiomics Market: Type Estimates & Trend Analysis
9. Multiomics Market: Platform Estimates & Trend Analysis
10. Multiomics Market: Application Estimates & Trend Analysis
11. Multiomics Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Multiomics Market
14. Europe Global Multiomics Market
15. Asia Pacific Global Multiomics Market
16. Latin America Global Multiomics Market
17. MEA Global Multiomics Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Shimadzu Corporation
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- Illumina Inc
- BGI
- Danaher
- BD
- QIAGEN
- PerkinElmer Inc.
- Bruker
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.34 Billion |
| Forecasted Market Value ( USD | $ 11.4 Billion |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
